Deal Watch: Merck’s Next Move In Cancer Immunotherapy Is BET Inhibitor, Bispecifics Gaining Steam
Executive Summary
Pfizer pays Opko $295 million up front for global rights to develop and commercialize a long-acting recombinant human growth hormone, Roche and Novo Nordisk buy into bispecific technology and Janssen signs on with Halozyme, as Pfizer did two years earlier, to use the ENHANZE delivery platform technology with its own candidates against five targets.
You may also be interested in...
Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
Durect Seeks Posidur Partner As It Continues Without A Marketed Drug
The specialty pharma is hoping to sign another partner to help finish developing the injectable pain medication and bring it to market after FDA issued a “complete response” letter in February.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.